Glutamate neurotoxicity and diseases of the nervous system

The recent identification of cannabinoid receptors and their endogenous lipid ligands has triggered an exponential growth of studies exploring the endocannabinoid system and its regulatory functions in health and disease. Such studies have been greatly facilitated by the introduction of selective cannabinoid receptor antagonists and inhibitors of endocannabinoid metabolism and transport, as well as mice deficient in cannabinoid receptors or the endocannabinoid-degrading enzyme fatty acid amidohydrolase. In the past decade, the endocannabinoid system has been implicated in a growing number of physiological functions, both in the central and peripheral nervous systems and in peripheral organs. More importantly, modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathological conditions, ranging from mood and anxiety disorders, movement disorders such as Parkinson9s and Huntington9s disease, neuropathic pain, multiple sclerosis and spinal cord injury, to cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity/metabolic syndrome, and osteoporosis, to name just a few. An impediment to the development of cannabinoid medications has been the socially unacceptable psychoactive properties of plant-derived or synthetic agonists, mediated by CB 1 receptors. However, this problem does not arise when the therapeutic aim is achieved by treatment with a CB 1 receptor antagonist, such as in obesity, and may also be absent when the action of endocannabinoids is enhanced indirectly through blocking their metabolism or transport. The use of selective CB 2 receptor agonists, which lack psychoactive properties, could represent another promising avenue for certain conditions. The abuse potential of plant-derived cannabinoids may also be limited through the use of preparations with controlled composition and the careful selection of dose and route of administration. The growing number of preclinical studies and clinical trials with compounds that modulate the endocannabinoid system will probably result in novel therapeutic approaches in a number of diseases for which current treatments do not fully address the patients9 need. Here, we provide a comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy.

http://www.phytecs.com/wp-content/uploads/2015/02/Pharmacol-Rev-2006-Pacher-389-462.pdf

The Endocannabinoid System as an Emerging Target of Pharmacotherapy

The endocannabinoids are a family of lipid messengers that engage the cell surface receptors that are targeted by Δ9-tetrahydrocannabinol, the active principle in marijuana (Cannabis). They are made on demand through cleavage of membrane precursors and are involved in various short-range signalling processes. In the brain, they combine with CB1 cannabinoid receptors on axon terminals to regulate ion channel activity and neurotransmitter release. Their ability to modulate synaptic efficacy has a wide range of functional consequences and provides unique therapeutic possibilities.

/pdf/the-molecular-logic-of-endocannabinoid-signalling-4bguoe2w8n.pdf

The molecular logic of endocannabinoid signalling

Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage.

The discovery of cannabinoid receptors and subsequent identification of their endogenous ligands (endocannabinoids) in early 1990s have greatly accelerated research on cannabinoid actions in the br...

Endocannabinoid-Mediated Control of Synaptic Transmission

Endogenous cannabinoids (endocannabinoids) are endogenous compounds that resemble the active ingredient of marijuana and activate the cannabinoid receptor in the brain. They mediate retrograde signaling from principal cells to both inhibitory ["depolarization-induced suppression of inhibition" (DSI)] and excitatory ("depolarization-induced suppression of excitation") afferent fibers. Transient endocannabinoid release is triggered by voltage-dependent Ca(2+) influx and is upregulated by group I metabotropic glutamate receptor activation. Here we show that muscarinic acetylcholine receptor (mAChR) activation also enhances transient endocannabinoid release (DSI) and induces persistent release. Inhibitory synapses in the rat hippocampal CA1 region of acute slices were studied using whole-cell patch-clamp techniques. We found that low concentrations (0.2-0.5 microm) of carbachol (CCh) enhanced DSI without affecting basal evoked IPSCs (eIPSCs) by activating mAChRs on postsynaptic cells. Higher concentrations of CCh (> or =1 microm) enhanced DSI and also persistently depressed basal eIPSCs, mainly by releasing endocannabinoids. Persistent CCh-induced endocannabinoid release did not require an increase in [Ca2+]i but was dependent on G-proteins. Although they were independent at the receptor level, muscarinic and glutamatergic mechanisms of endocannabinoid release shared intracellular machinery. Replication of the effects of CCh by blocking acetylcholinesterase with eserine suggests that mAChR-mediated endocannabinoid release is physiologically relevant. This study reveals a new role of the muscarinic cholinergic system in mammalian brain.

https://www.jneurosci.org/content/jneuro/22/23/10182.full.pdf

Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus

https://www.cell.com/trends/neurosciences/pdf/S0166-2236(11)00040-3.pdf

Supply and demand for endocannabinoids

In hippocampal pyramidal cells, a rise in Ca(2+) releases endocannabinoids that activate the presynaptic cannabinoid receptor (CB1R) and transiently reduce GABAergic transmission-a process called depolarization-induced suppression of inhibition (DSI). The mechanism that limits the duration of endocannabinoid action in intact cells is unknown. Here we show that inhibition of cyclooxygenase-2 (COX-2), not fatty acid amide hydrolase (FAAH), prolongs DSI, suggesting that COX-2 limits endocannabinoid action.

Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus

We studied paired-pulse depression (PPD) of GABA A ergic IPSCs under conditions of reduced transmitter release (caused by Cd 2+ , baclofen, or reduced stimulus intensity) with whole-cell voltage clamp in CA1 pyramidal cells in vitro . The use-dependent model of paired-pulse responsiveness holds that a decrease in the probability of neurotransmitter release during the first stimulus will cause predictable changes in the paired-pulse ratio (PPR, the amplitude of the second IPSC divided by that of the first). However, the applicability of the use-dependent model to inhibitory synapses is controversial. Our results are inconsistent with this model, but are consistent with the hypothesis that random fluctuations in response size significantly influence PPR. PPR was sensitive to the extracellular stimulus intensity in all conditions. Changes in PPR were not correlated with changes in the first IPSC, but were correlated with changes in variability of the PPRs of individual traces. We show that spurious paired-pulse facilitation (PPF) can result from averaging randomly fluctuating PPRs because the method of calculating PPR as the mean of individual PPRs is biased in favor of high values of PPR. Spurious PPF can mask the intrinsic paired-pulse property of the synapses. Calculating PPR as the mean of the second response divided by the mean of the first avoids the error. We discuss a simple model that shows that spurious PPF depends on both the number of synapses recruited for release and the probability of release at each release site. The random factor can reconcile some conflicting published conclusions.

https://www.jneurosci.org/content/jneuro/21/24/9608.full.pdf

Random response fluctuations lead to spurious paired-pulse facilitation

Although most inhibitory synapses are homeostatically scaled down after chronic inactivity, Kim et al. report that chronic inactivity specifically strengthens a subset of hippocampal GABAergic synapses that express cannabinoid receptors. This local tuning effect is mediated by enhanced degradation of anandamide, which reduces basal cannabinoid receptor activation, augmenting GABA release probability.

Jimok Kim

Papers

Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus

Supply and demand for endocannabinoids

Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus

Random response fluctuations lead to spurious paired-pulse facilitation

Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses